Eton Pharmaceuticals, Inc. (ETON)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$55.62+0.47%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.6B
- P/E (trailing)
- 139.1
- Forward P/E
- 21.6
- 52-week range
- $14.27 – $66.37
- 52-week change
- +167.05%
- EPS (trailing)
- $0.40
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $80.0M (+104.94%)
- Net income
- −$4.6M
- Operating margin
- −1.1%
- Free cash flow
- $10.2M
From the company’s annual report on SEC EDGAR.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Headquarters: Deer Park, United States · 44 employees · etonpharma.com